Management of Pregnant/Parenting Women With Opioid Use Disorder and Their Infants (1.5 CME)
(1.5 CME) In this conference recording from the 2018 Annual Conference, you will learn about the publication Clinical Guidance for Treating Pregnant and Parenting Women With Opioid Use Disorder (OUD) and Their Infants – a comprehensive Clinical Guide on managing optimal OUD care and treatment developed by the Substance Abuse and Mental Health Services Administration (SAMHSA). This Clinical Guide meets an urgent need among healthcare professionals who treat women with OUD and children exposed to substances by providing reliable information that can be applied in clinical practices to achieve positive outcomes for both mother and infant. It contains an introduction to the guide and fact sheets that include clinical scenarios, clinical action steps, supporting evidence, clinical considerations, and web resources.
The factsheets are organized into three sections:
- Section I – Prenatal Care (Factsheets #1–8)
- Section II – Infant Care (Factsheets #9–13)
- Section III – Maternal Postnatal Care (Factsheets #14–16)
The Clinical Guide is based on the recommendations published in Advancing the Care of Pregnant and Parenting Women With Opioid Use Disorder and Their Infants: A Foundation for Clinical Guidance.
This workshop will be moderated by Melinda Campopiano, MD, Medical Officer for SAMHSA’s Center for Substance Abuse Treatment. She and three members from the RAND/UCLA Appropriateness Method (RAM) expert panel will discuss treatment recommendations from the Clinical Guide. Audience members will have the opportunity to ask questions about the recommendations and the clinical care for pregnant and parenting women with OUD.
Charles W. Schauberger
MD, MS, CPE
Dr. Charles Schauberger is an obstetrician who practices at Gundersen Health System in La Crosse, Wisconsin. He attended University of Iowa Medical School and completed a residency in Obstetrics & Gynecology at the same location many years ago. He received a MS in Administrative Medicine from the University of Wisconsin- Madison. He has published over 40 articles in the peer review literature. He is passionate about the care of pregnant women with addictions.
Hendree Jones, PhD is a Professor in the Department of Obstetrics and Gynecology, School of Medicine, University of North Carolina, Chapel Hill and Executive Director of Horizons, a comprehensive drug treatment program for pregnant and parenting women and their drug-exposed children. She is also an Adjunct Professor in the Department of Psychology, UNC, Chapel Hill and an Adjunct Professor in the Psychiatry and Behavioral Sciences and in the Department of Obstetrics and Gynecology, School of Medicine, Johns Hopkins University.
Dr. Jones is an internationally recognized expert in the development and examination of both behavioral and pharmacologic treatments for pregnant women and their children in risky life situations. Dr. Jones has received continuous funding from the United States National Institutes of Health since 1994 and has published over 185 publications, two books on treating substance use disorders (one for pregnant and parenting women and the other for a more general population of patients), numerous book and textbook chapters. She is a consultant for SAMHSA, the United Nations and the World Health Organization.
Dr. Jones leads or is involved in projects in Afghanistan, the South America, the Republic of Georgia, South Africa, and the United States which are focused on improving the lives of children, women and families.
Dr. Coffa is the Residency Program Director for the Family and Community Medicine Residency program at the University of California, San Francisco. in addition to practicing full spectrum primary care, Dr. Coffa co-leads an addiction consultation clinic and directs the chronic pain programs at the Family Health Center, an FQHC teaching clinic. She oversees the clinic's buprenorphine program and ensures that residents in family medicine, internal medicine, pediatrics, obstetrics, and psychiatry have access to buprenorphine training. She is also the primary consultant for buprenorphine prescribing at Zuckerberg San Francisco General Hospital, providing clinical guidance to hospital and maternal care providers who are treating hospitlalized patients for opioid use disorder.
RPH, DO, CDR, USPHS
Dr. Anthony Campbell is currently a board eligible candidate in the field of addiction medicine who currently services as a Clinical Specialty Consultant with the Substance Abuse and Mental Health Services Administration, Center for Substance Abuse Treatment in the Division of Pharmacologic Therapies (SAMHSA/CSAT/DPT). He and serves as a Commander in the United States Public Health Service. In his role at SAMHSA, he is responsible for planning, directing and evaluating the development of pharmacotherapy-based treatment standards and guidelines that require specialized DPT medical review. In addition he is an adjunct professor at both Howard University Colleges of Pharmacy and Medicine in Washington DC.
Dr. Campbell earned two bachelor’s degrees from Howard University; Chemistry (85) and Pharmacy (88). He earned his Doctorate of Osteopathic Medicine from Ohio University (94). Additional training followed including a residency in Internal Medicine, with current board certification.
ACCME Accreditation Statement
The American Society of Addiction Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
AMA Credit Designation Statement
The American Society of Addiction Medicine designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
ABPM Maintenance of Certification (MOC)
The American Board of Preventive Medicine (ABPM) has approved this activity for a maximum of 1.5 LLSA credits towards ABPM MOC Part II requirements.
ABAM Transitional Maintenance of Certification (tMOC)
This course has been approved by the American Board of Addiction Medicine (ABAM). Physicians enrolled in the ABAM Transitional Maintenance of Certification Program (tMOC) can apply a maximum of 1.5 AMA PRA Category 1 Credit(s)™ for completing this course.